Literature DB >> 28537650

Tendon healing induced by chemically modified mRNAs.

K Groth, T Berezhanskyy, M K Aneja, J Geiger, M Schweizer, L Maucksch, T Pasewald, T Brill, B Tigani, E Weber, C Rudolph1, G Hasenpusch.   

Abstract

Tendon disorders are frequent both in human and veterinary medicine with high re-injury rates and unsatisfactory therapeutic treatments. Application of naked, chemically-modified mRNA (cmRNA), encoding for therapeutic proteins, is an innovative approach to address tendon healing. In the current study, we demonstrated that injection of naked cmRNA, diluted in a glucose-containing solution, into tendons resulted in high protein expression in healthy and experimentally-injured tendons. Injection of bone morphogenetic protein 7 (BMP-7)-encoding cmRNA resulted in a significantly higher expression of BMP-7 protein and reduced formation of collagen type III, compared to vehicle control. Moreover, in a large animal model, reporter protein expression was detectable not only in healthy, but also in experimentally-injured, severely inflamed tendons. Summarising, these results demonstrated the potential of cmRNAs encoding for therapeutic proteins as a new class of drugs for the treatment of tendon disorders.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28537650     DOI: 10.22203/eCM.v033a22

Source DB:  PubMed          Journal:  Eur Cell Mater        ISSN: 1473-2262            Impact factor:   3.942


  6 in total

1.  Delivery of hepatocyte growth factor mRNA from nanofibrillar scaffolds in a pig model of peripheral arterial disease.

Authors:  Tatiana S Zaitseva; Guang Yang; Dimitris Dionyssiou; Maedeh Zamani; Steve Sawamura; Eduard Yakubov; James Ferguson; Richard L Hallett; Dominik Fleischmann; Michael V Paukshto; Ngan F Huang
Journal:  Regen Med       Date:  2020-08-10       Impact factor: 3.806

2.  Aligned Nanofibrillar Scaffolds for Controlled Delivery of Modified mRNA.

Authors:  Tatiana S Zaitseva; Cynthia Alcazar; Maedeh Zamani; Luqia Hou; Steve Sawamura; Eduard Yakubov; Michael Hopkins; Y Joseph Woo; Michael V Paukshto; Ngan F Huang
Journal:  Tissue Eng Part A       Date:  2018-06-20       Impact factor: 3.845

3.  Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy.

Authors:  Frank DeRosa; Lianne Smith; Yinghua Shen; Yan Huang; Jing Pan; Hongsheng Xie; Barak Yahalom; Michael W Heartlein
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

Review 4.  Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases.

Authors:  Dana Elkhalifa; Menatallah Rayan; Ahmed T Negmeldin; Abdelbary Elhissi; Ashraf Khalil
Journal:  Biomed Pharmacother       Date:  2021-10-28       Impact factor: 6.529

5.  Gelatin Nanoparticles for Complexation and Enhanced Cellular Delivery of mRNA.

Authors:  Lea Andrée; Rik Oude Egberink; Josephine Dodemont; Negar Hassani Besheli; Fang Yang; Roland Brock; Sander C G Leeuwenburgh
Journal:  Nanomaterials (Basel)       Date:  2022-09-29       Impact factor: 5.719

Review 6.  mRNA as novel technology for passive immunotherapy.

Authors:  Thomas Schlake; Andreas Thess; Moritz Thran; Ingo Jordan
Journal:  Cell Mol Life Sci       Date:  2018-10-17       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.